NCT05057247View on ClinicalTrials.gov

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

October 1, 2023

Study Completion Date

January 1, 2026

Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN)Recurrent Squamous Cell Carcinoma of the Head and NeckMetastatic Head and Neck CancerAdvanced Head and Neck CancerAdvanced Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Duvelisib

"Duvelisib capsules should be swallowed whole with a glass of water (approximately 8 ounces).~Advise patients not to open, break, or chew the capsules. Duvelisib may be administered without regard to meals; however, subjects should avoid grapefruit and grapefruit juice while on duvelisib.~continue for up to 24 months."

DRUG

Docetaxel

Docetaxel chemotherapy once every 21 days (by intravenous infusion) over about 30- 60 minutes at each visit. This will continue for up to 24 months

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Secura Bio, Inc.

INDUSTRY

lead

Glenn J. Hanna

OTHER